Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
Waltham, Mass., June 20, 2017 — Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, today announced that its F1RST Up™ alliance of clinical research sites focusing on kidney disease has expanded to include 55 physician investigators representing 23 sites.
“The success of F1RST Up is clear evidence of the value the alliance provides to our sponsor clients, our alliance partners and to other contract research organizations (CROs) we collaborate with,” said Kurt Mussina, general manager of Frenova. “F1RST Up accelerates study startup by taking a no-nonsense approach to driving low-value administrative and contracting burdens out of the startup process. This provides our partners and customers with a better startup experience, equating to much better value.”
The F1RST Up alliance membership includes nephrology practices caring for large numbers of chronic kidney disease (CKD) patients, including end stage renal disease (ESRD) patients. F1RST Up investigators are highly experienced clinical researchers in renal disease and its adjacencies, including vascular access and care, cardio-renal conditions, rare diseases, infectious diseases and transplant. The alliance leverages Frenova’s access to proprietary clinical research assets to inform protocol design and to carry out highly targeted and efficient patient recruitment efforts.
“We formed this alliance with the leading physician investigators from across Frenova’s network of 260 clinical research sites,” said Christina Kahn, Frenova’s F1RST Up alliance lead. “This is important because it means F1RST Up offers sponsors access to a uniquely concentrated source of both high quality renal research sites and a substantial number of patients.”
To learn more about Frenova F1RST Up, visit FrenovaRenalResearch.com/F1RST-Up.
About Frenova Renal Research
Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including over 450 principal investigators at more than 260 sites representing 160 medical practices. Frenova manages clinical trials in kidney disease and its adjacent medical conditions. When you need to conduct a complete renal clinical program, trust the partner that’s completely renal — Frenova Renal Research. Visit www.FrenovaRenalResearch.com for more information.